Fujifilm Medical Systems USA will unveil new products in computed and digital radiography, as well as digital mammography and information technology at the RSNA 2009 meeting.
Fujifilm Medical Systems USA will unveil new products in computed and digital radiography, as well as digital mammography and information technology at the RSNA 2009 meeting. Currently pending FDA clearance, its FDR (Fuji digital radiography) AcSelerate system features a fully automated table and upright stand and ergonomic design that the company say makes the system easier to use, position and operate than traditional systems.
Also debuting on the RSNA exhibit floor will be the company’s full field digital mammography (FFDM) system, Aspire-HD. Already in clinical use outside the U.S. but still pending FDA clearance, the Aspire HD offers a 24 x 30cm amorphous selenium detector that minimizes dose and produces images with low noise and high spatial resolution, utilizing pixels measuring 50 microns. A unique bucky design addresses patient comfort, while assuring optimal access to the chest wall. It will be configured with an FDA-pending color workstation, called the AWS c, which is designed to better illustrate patient data and image exposure information.
Fujifilm will also introduce its second generation of CR-based FFDM systems at RSNA 2009. This latest version of the Aspire ClearView reader will continue to provide 50 micron resolution and dual-side detector reading. Enhancements include a sleeker look, lighter weight, wider viewing angle on the LCD and the AWS c color workstation.
On the IT side, Fujifilm will show its Synapse cardiovascular version 4.0.4, a Web-based cardiovascular image and information management solution, featuring third party integrations that help clinicians access patient data stored in other locations. Interfaces to ViTALConnect for advanced 3D/4D analysis and GE MUSE Web, for access to ECG data are two new options. The enhanced Synapse product will also work with GE EchoPAC for import, storage and viewing of EchoPAC-created final reports and with Medis Medical QAngio XA for analysis of the left ventricle and coronary vessels in angiograms.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.